Key facts
- This page summarizes Kyle Moran's Form 4 filing for Wave Life Sciences Ltd. (WVE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 May 2022, 19:10.
Kyle Moran - 04 May 2022 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- WVE
- Reported as of
- 04 May 2022
- Net transaction value
- -$8,636
- SEC form
- 4
- Accepted by SEC
- 06 May 2022, 19:10:10 UTC
- Prior SEC filing
- 18 Feb 2022
- Next SEC filing
- 27 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kyle Moran
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kyle Moran filed Form 4 for Wave Life Sciences Ltd. (WVE) on 06 May 2022.
Change
- Previous filing in this sequence was filed on 18 Feb 2022.
- Current net transaction value: -$8,636.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
WVE
transaction
Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- +20%
- Price
- $0.000000
- Shares after
- 89,588
- Date
- 04 May 2022
- Ownership
- Direct
- Footnotes
- F1
WVE
transaction
Ordinary Shares
Sale
- Transaction value
- $8,636
- Shares
- -5,021
- Change %
- -5.6%
- Price
- $1.72
- Shares after
- 84,567
- Date
- 05 May 2022
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
On March 7, 2019, the reporting person received performance-based restricted share units ("PSUs"), convertible on a one-for-one basis into ordinary shares of the issuer upon vesting. On May 4, 2022, 50% of the PSUs vested upon the issuer's achievement of the PN Chemistry Milestone (as defined in the PSU agreement) following the issuer's recent WVE-004 data release, as certified by the issuer's compensation committee.
Footnote F2
On May 5, 2022, the reporting person sold 5,021 ordinary shares solely to cover taxes associated with the vesting of the PSUs on May 4, 2022. These sales were made pursuant to a provision in the reporting person's PSU agreement that requires automatic sales of shares to cover tax withholding obligations. The sales are intended to comply with Rule 10b5-1(c)(1)(i)(B) under the Securities Exchange Act of 1934, as amended.
Footnote F3
The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.72 to $1.741 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.